Background and purpose Spinal muscular atrophy (SMA) is caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations in the SMN1 gene. Risdiplam is an orally administered molecule that modifies SMN2 pre-mRNA splicing to increase functional SMN protein. Methods SUNFISH Part 1 was a dose-finding study conducted in 51 individuals with types 2 and 3 SMA aged 2-25 years. A dose-escalation method was used to identify the appropriate dose for the subsequent pivotal Part 2. Individuals were randomized (2:1) to risdiplam or placebo at escalating dose levels for a minimum 12-week, double-blind, placebo-controlled period, followed by treatment for 24 months. The dose selection for Part 2 was based on safety, tolerability, pharmacokinetic, and pharmacodynamic data. Exploratory efficacy was also measured. Results There was no difference in safety findings for all assessed dose levels. A dose-dependent increase in blood SMN protein was observed; a median twofold increase was obtained within 4 weeks of treatment initiation at the highest dose level. The increase in SMN protein was sustained over 24 months of treatment. Exploratory efficacy showed improvement or stabilization in motor function. The pivotal dose selected for Part 2 was 5 mg for patients with a body weight >= 20 kg or 0.25 mg/kg for patients with a body weight <20 kg. Conclusions SUNFISH Part 1 demonstrated a twofold increase in SMN protein after treatment with risdiplam. The observed safety profile supported the initiation of the pivotal Part 2 study. The long-term efficacy and safety of risdiplam are being assessed with ongoing treatment.

Mercuri, E., Baranello, G., Boespflug-tanguy, O., De Waele, L., Goemans, N., Kirschner, J., Masson, R., Mazzone, E. S., Pechmann, A., Pera, M. C., Vuillerot, C., Bader-weder, S., Gerber, M., Gorni, K., Hoffart, J., Kletzl, H., Martin, C., Mciver, T., Scalco, R. S., Yeung, W. Y., Servais, L., Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment, <<EUROPEAN JOURNAL OF NEUROLOGY>>, 2022; (N/A): N/A-N/A. [doi:10.1111/ene.15499] [http://hdl.handle.net/10807/213585]

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment

Mercuri, Eugenio;Mazzone, Elena S;Pera, Maria Carmela;
2022

Abstract

Background and purpose Spinal muscular atrophy (SMA) is caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations in the SMN1 gene. Risdiplam is an orally administered molecule that modifies SMN2 pre-mRNA splicing to increase functional SMN protein. Methods SUNFISH Part 1 was a dose-finding study conducted in 51 individuals with types 2 and 3 SMA aged 2-25 years. A dose-escalation method was used to identify the appropriate dose for the subsequent pivotal Part 2. Individuals were randomized (2:1) to risdiplam or placebo at escalating dose levels for a minimum 12-week, double-blind, placebo-controlled period, followed by treatment for 24 months. The dose selection for Part 2 was based on safety, tolerability, pharmacokinetic, and pharmacodynamic data. Exploratory efficacy was also measured. Results There was no difference in safety findings for all assessed dose levels. A dose-dependent increase in blood SMN protein was observed; a median twofold increase was obtained within 4 weeks of treatment initiation at the highest dose level. The increase in SMN protein was sustained over 24 months of treatment. Exploratory efficacy showed improvement or stabilization in motor function. The pivotal dose selected for Part 2 was 5 mg for patients with a body weight >= 20 kg or 0.25 mg/kg for patients with a body weight <20 kg. Conclusions SUNFISH Part 1 demonstrated a twofold increase in SMN protein after treatment with risdiplam. The observed safety profile supported the initiation of the pivotal Part 2 study. The long-term efficacy and safety of risdiplam are being assessed with ongoing treatment.
Inglese
Mercuri, E., Baranello, G., Boespflug-tanguy, O., De Waele, L., Goemans, N., Kirschner, J., Masson, R., Mazzone, E. S., Pechmann, A., Pera, M. C., Vuillerot, C., Bader-weder, S., Gerber, M., Gorni, K., Hoffart, J., Kletzl, H., Martin, C., Mciver, T., Scalco, R. S., Yeung, W. Y., Servais, L., Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment, <<EUROPEAN JOURNAL OF NEUROLOGY>>, 2022; (N/A): N/A-N/A. [doi:10.1111/ene.15499] [http://hdl.handle.net/10807/213585]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/213585
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact